What's Inside


Psychiatry Home

CNC Administrative Center

MNDrive Logo
Learn more about new neuromodulation therapies and treatments at the
U of M


 

 
  Home > Research Activities > Schizophrenia Program
 

Schizophrenia Program

Stephen Olson, M.D.

Director

To learn more about the research studies below contact:

Victoria Patrick, CCRC

University of Minnesota Ambulatory Research Center
Schizophrenia Program Coordinator
Office: (612) 626-7635
E-mail: vpatrick@umn.edu

For more information or to learn more about schizophrenia or other psychotic disorders, email schizophrenia@umn.edu.

Current Schizophrenia Studies

SCHIZOPHRENIA STUDY


Researchers at the University of Minnesota are exploring an investigational once-monthly injection of aripiprazole. The idea behind this approach is to help patients with schizophrenia better manage their condition. This injectable drug is being explored as part of the ARRIVE study. If you are eligible and choose to participate in this study, you will receive all study related care and drugs at no cost to you. Aripiprazole is approved in an oral form to be taken daily by patients with schizophrenia. The study drug being explored as part of the ARRIVE study is an investigational long-acting injectable form of aripiprazole. This long-acting injectable drug is designed to be taken just once a month. It is thought that this approach may help people with schizophrenia to improve their management of the disease. For more information, please contact Victoria at (612) 626-7635 or email vpatrick@umn.edu.

BRAIN TRAINING / COGNITION STUDY FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER

Are you having problems with concentration or memory and are already taking Latuda ®(lurasidone)? Research volunteers for a study of computer-based brain exercises (cognitive remediation) are needed. Subjects should already be stabilized on the FDA-approved antipsychotic medication, lurasidone (Latuda®) and then do thirty sessions of brain training. All study-related psychiatric care, cognitive testing, and medication are provided for 4-6 months, as well as travel expenses and compensation of up to $450.00. The study is conducted by the Schizophrenia Program at the University of Minnesota. For more information, please contact Victoria at (612) 626-7635 or e-mail vpatrick@umn.edu.

Proteomic Diagnostic Test for Schizophrenia

The University of Minnesota Psychiatry Department is looking for individuals between the ages if 15 and 65 who have been diagnosed with schizophrenia, schizoaffective disorder, bipolar disorder, psychosis secondary to drug abuse, or who are currently being treated because they are at risk of developing psychosis. The aim of this study is to examine proteins in the blood and see how they relate to psychosis. Our hope is that the information we obtain through this research will contribute to a greater understanding of psychosis and increase effectiveness of treatment for the disorder.

We are currently screening and enrolling participants for this study. If interested, participants will be invited to an initial evaluation to address any questions or concerns they may have, and to assess eligibility for the study. The initial evaluation will consist of a clinical assessment, short physical exam, a cognitive assessment, a urine test, and a blood draw. If included in the study, participants will be asked to attend monthly follow-ups for 9 months which will be comprised of a short assessment of health or symptom changes, a urine test, and a blood draw. Participation in this study could help to improve the ability to diagnose and treat schizophrenia and other psychotic disorders. All information obtained from participants is kept strictly confidential. This is not a medication trial and you will not be asked to take any drugs or seek any additional treatment. All participants will be compensated $40 for their initial and final visits as well as $25 dollars for each monthly visit. All transportation costs will also be covered.

For more information regarding possible participation in this study, please call the study’s research coordinator, Brian Ginter: 612-627-4372 or email: gint0042@umn.edu.

Volunteers Needed for Brain Imaging Study at the U of MN Medical School Department of Psychiatry

If you are 14 to 18 years of age, you may be eligible to participate. The study includes an MRI brain scan, clinical interview, questionnaires, and neuro-psychological testing. Feedback & stipend provided.

For more information, please call Caroline at 612-273-9733.

Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia (SCRP)

The University of Minnesota, Ambulatory Research Center is seeking smokers who smoke more than 10 cigarettes/day, with schizophrenia or schizoaffective disorder, and in good health for a research study evaluating varenicline (Chantix). The quit smoking study that we are conducting involves a medication called Chantix that was specifically designed to help people quit smoking. Medication treatment will last for 12 weeks and participants will attend weekly cognitive-behavioral therapy groups, in which we talk about our thoughts and behaviors around our smoking, triggers, and cravings. Each meeting will last for a little over an hour. After attending group meetings and taking the study medication for 4 weeks, we will help you set a quit date and ask you to quit smoking. If you are able to quit smoking and you have been quit for at least two weeks by the end of the program, we will give you the option of enrolling in the relapse prevention segment of this study to help you stay quit. The relapse prevention phase lasts for 40 weeks and participants will continue the group sessions and receive either Chantix or placebo tablets. At each group meeting, we will monitor your blood pressure and pulse and ask you how you feel physically and mentally to make sure that you are doing alright with the medication.   In addition to group meetings, you will be asked to come in for a few individual visits throughout the study to answer some questions and sometimes to perform some computer tasks. Your first individual visit with a member of our study staff will occur before the group starts; this visit will be to conduct a more comprehensive screening to see if you are eligible for the study. At that time, we would also explain the study to you in greater detail and answer any questions you might have about it. Participants will be compensated for their time. For more information, please call: 612-627-4840.

Schizophrenia Brain Imaging Study at U of M

Volunteers are needed for a brain imaging study at the University of Minnesota, Medical School, Department of Psychiatry.  If you have Schizophrenia or other related illnesses, and are between the ages of 16 and 60, you may be eligible for a MRI study.  This is not a medication trial. A stipend is offered.  For more information, please call (612) 627-4825.  Flexible appointments are available to fit your scheduling needs. 

Do you have schizophrenia? You maybe able to help advance understanding of schizophrenia.

We invite individuals diagnosed with schizophrenia or schizoaffective disorder that are between the ages of 18 and 65 to participate in a research study of thoughts and behavior in people with schizophrenia.  The study is conducted by Dr. Angus MacDonald in the Department of Psychology.  This study calls for participants to make 3 visits (each lasting between 1.5 and 3 hours), complete confidential drug and alcohol testing, provide a saliva sample, answer questions of a personal nature and complete button-pressing tasks. Compensation for participation is $20/hour. All information will be kept confidential. Contact the TRiCAM Lab at the University of Minnesota in Minneapolis: Call Edward at 612-624-3892 or Complete our confidential on-line survey and we will call you: https://survey.cla.umn.edu/tricam



 
What's Inside

Related Links

Translational Research in Cognitive and Affective Mechanism (TRiCAM) laboratory

National Institute on Mental Health

National Alliance on Mental Illness-Minnesota Chapter

Schizophrenia Information

Clinical Trials Information

National Institute of Health

Center for Disease Control

U.S. Drug and Food Administration


Notice of Privacy Practices